Abstract
A study published in 2012 analyzed more than three dozen drug and device companies’ Medical Science
Liaison (MSL) operations around the world. The study revealed that the top 20 pharmaceutical organizations
invest between $10 million and $48 million to deploy MSLs in the US, Europe and Asia.